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Abstract
Background. Multiple criteria decision analysis (MCDA) has been identified as a prospective methodology for assist-
ing decision makers in evaluating the benefits of new medicines in health technology assessment (HTA); however,
limited empirical evidence exists from real-world applications. Objective. To test in practice a recently developed
MCDA methodological framework for HTA, the Advance Value Framework, in a proof-of-concept case study with
decision makers. Methods. A multi-attribute value theory methodology was adopted applying the MACBETH ques-
tioning protocol through a facilitated decision-analysis modelling approach as part of a decision conference with four
experts. Settings. The remit of the Swedish Dental and Pharmaceutical Benefits Agency (Tandva˚rds- och la¨kemedels-
fo¨rma˚nsverket [TLV]) was adopted but in addition supplementary value dimensions were considered. Patients.
Metastatic castrate-resistant prostate cancer patients were considered having received prior chemotherapy.
Interventions. Abiraterone, cabazitaxel, and enzalutamide were evaluated as third-line treatments. Measurements.
Participants’ value preferences were elicited involving criteria selection, options scoring, criteria weighting, and their
aggregation. Results. Eight criteria attributes were finally included in the model relating to therapeutic impact, safety
profile, socioeconomic impact, and innovation level with relative importance weights 44.5%, 33.3%, 14.8%, and
7.4% per cluster, respectively. Enzalutamide scored the highest overall weighted preference value score, followed by
abiraterone and cabazitaxel. Dividing treatments’ overall weighted preference value scores by their costs derived
‘‘costs per unit of value’’ for ranking the treatments based on value-for-money grounds. Limitations. Study limita-
tions included lack of comparative clinical effects across treatments and the small sample of participants. Conclusion.
The Advance Value Framework has the prospects of facilitating the evaluation process in HTA and health care deci-
sion making; additional research is recommended to address technical challenges and optimize the use of MCDA for
policy making.
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In recent years, the assessment and appraisal of new medi-
cines by health technology assessment (HTA) agencies and
payer bodies for the purpose of pricing and reimbursement
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has received considerable attention. At times, this has
emerged as a consequence of negative coverage decisions
for some medicines, often related to treatments for high-
burden diseases associated with significant mortality and
morbidity. As a consequence, intense disputes for the allo-
cation of resources often arise usually involving patients,
clinicians, and pharmaceutical manufacturers on one hand
and HTA agencies, commissioners of care, and public deci-
sion makers on the other.
To a large extent this conflict can be attributed to current
methodologies used for the evaluation of new medicines as
they cannot adequately capture the different notions of
value evident given the existence of diverse perspectives.1
For example, despite the fact that the QALY (quality-
adjusted life-year) metric has managed to successfully com-
bine the two vital dimensions of health benefit relating to life
expectancy and health-related quality of life (HRQoL), its
sole and inflexible adoption as part of economic evaluations
in HTA can at times be regarded as blunt and insufficient,
not least because it does not reflect other important value
dimensions of treatments.2,3 This lack of comprehensiveness
has led decision makers to use additional parameters of
value in an informal and nonsystematic manner, often
diminishing transparency in the evaluation procedures,4
with emerging inconsistencies in coverage threatening the
credibility of the decision outcomes and their acceptance or
perceived fairness from the public.
More recently, a growing number of resource-
conscious health care professionals have started to pub-
licly oppose the use of highly expensive new drugs in
clinical practice that are perceived to bring marginal
added clinical benefit on the grounds of poor value for
money. Escalating drug prices have catalyzed the genera-
tion of numerous ‘‘value frameworks’’ with the aim to
inform payers, clinicians, and patients around the assess-
ment process of new medicines for the purpose of cover-
age and treatment selection decisions.5–8 Although this is
an important step toward a more inclusive value-based
assessment approach and should be supported,9 aspects
of these frameworks might be based on weak or
atheoretical methodologies and could potentially result
in misleading recommendations or decisions.10
Research and development of alternative methodologies
for assessing and appraising the value of new medicines
could overcome such limitations, contributing toward a
more complete framework for measuring value and mak-
ing resource allocation and treatment decisions. Multiple
criteria decision analysis (MCDA) has recently surfaced as
an alternative method not only to traditional economic
evaluation techniques with the prospects of addressing
some of their limitations in HTA11–18 but also for eliciting
patient preferences and facilitating treatment selection.19–21
In any case, empirical evidence from real-world applica-
tions with HTA decision makers are very limited.
This is a proof-of-concept case study in an HTA context
applying a recently developed value framework,
the Advance Value Framework (AVF),22,23 for assessing
the value of metastatic castrate-resistant prostate cancer
(mCRPC) treatment options following second-line che-
motherapy. This corresponds to the first of a series of case
studies that test in practice the AVF by engaging with and
eliciting the preferences of decision makers from national
HTA agencies and payer bodies in Europe. It forms conti-
nuation of pilot work from an earlier case study on the
assessment of drugs for metastatic colorectal cancer using
value judgements from a range of stakeholders in the
English setting.24 A facilitated workshop was organized tak-
ing the form of a decision conference,25 adopting a facili-
tated decision analysis modelling approach,26,27 and
involving an experts panel of assessors from the Swedish
Dental and Pharmaceutical Benefits Agency (Tandva˚rds-
och la¨kemedelsfo¨rma˚nsverket [TLV]). Metastatic prostate
cancer was chosen as a case study topic mainly because of
its high disease severity and the availability of several expen-
sive treatment options that highlight a clear decision prob-
lem. This indication has been a popular appraisal topic by
numerous HTA agencies, including TLV in Sweden and
the National Institute for Health and Care Excellence
(NICE) in England.
The adaptation of the AVF for the metastatic prostate
cancer setting is described in the Methods section, the
rankings of the treatment options based on their value
are shown in the Results section, with limitations of the
methodology and challenges of MCDA applications in
HTA presented in the Discussion section.
Methods
Methodological Framework
The AVF was applied for assessing the value of a set of
drug treatments, similarly to a previous application for
Medical Technology Research Group, LSE Health and Department of
Health Policy, London School of Economics and Political Science,
London, UK. The author(s) declared no potential conflicts of interest
with respect to the research, authorship, and/or publication of this arti-
cle. Financial support for this study was provided entirely by a grant
from the European Commission, DG Research (Advance HTA project,
Grant Number 305983). The funding agreement ensured the author’s
independence in designing the study, interpreting the data, writing, and
publishing the report. The views represented in the article do not neces-
sarily reflect the views of the European Commission.
2 MDM Policy & Practice 00(0)
another oncology indication.24 This methodology adopts
an MCDA ‘‘clean-slate’’ approach for HTA12 based on
multi-attribute value theory (MAVT),28,29 with the aim
to derive a comprehensive value function following five
iterative phases: 1) problem structuring, 2) model build-
ing, 3) model assessment, 4) model appraisal, and 5)
development of action plans.23 The AVF was operatio-
nalized using the decision support system
M-MACBETH, enabling the use of visual graphics to
build a model of values, acting as a facilitation tool to
inform both the design phases (1 and 2) and evaluation
phases (3 and 4) of the methodological process.30
Additional information on the methodological process
can be found in the Online Supplementary Appendix.
Clinical Practice and Scope of the Exercise
(Problem Structuring)
In 2004, clinical evidence demonstrated the survival ben-
efit of docetaxel chemotherapy in combination with pre-
dnisolone for castrate-resistant prostate cancer (CRPC)
patients, when compared with mitoxantrone in combina-
tion with prednisolone.31,32 Since then a fruitful period in
the development of prostate cancer drugs followed with a
number of new molecules indicating significant clinical
benefit in patients previously treated with docetaxel
including abiraterone, cabazitaxel, and enzalutamide.33–35
Cross-resistance appears to exist between abiraterone and
enzalutamide, indicating that it is unlikely to experience
clinical benefit by switching from one treatment to the
other,36,37 based on which NICE recommends only the
use of either treatment and not both.38,39 Although spe-
cific patient subpopulations might be contraindicated to
any of the treatments, in most cases all three new and
expensive drugs could be suitable for patients, and there-
fore, the topic of CRPC treatment coverage acts as a suit-
able decision context for the application of the value
framework.
The analysis presented here focuses on assessing the
value of third-line treatments for mCRPC following
prior docetaxel-containing (i.e., second line) chemother-
apy, essentially adopting the clinical practice guidelines
from the European Society for Medical Oncology
(ESMO) and the scopes of the respective Technology
Appraisals (TAs) for each technology by NICE and
TLV. In doing so, the same clinical evidence from the
corresponding TAs was used to inform the respective cri-
teria of the value tree, but this was further supplemented
by additional evidence for value concerns not explicitly
addressed by NICE and TLV. The scope of NICE
TA255 was adopted for the case of cabazitaxel in
combination with prednisone, the scope of NICE TA259
and TLV TA4774/2014 was adopted for the case of abir-
aterone in combination with prednisone, whereas the
scope of NICE TA316 and TLV TA2775/2013 was
adopted for the case of enzalutamide.38–42
Adaptation of the Advance Value Tree for
Metastatic Prostate Cancer (Model Building)
Selection of evaluation criteria benefitted from a hybrid
approach, which essentially combined features from
‘‘value focused thinking’’43 and ‘‘alternative focused
thinking.’’44 Initially, a top-down approach was adopted
for the selection of a general set of evaluation criteria by
decomposing the overall value concerns of HTA decision
makers into subconcerns, which took place prior to the
selection of any drug options; this was followed by the
adaptation of the general criteria into disease-specific cri-
teria, which took place after comparing the characteris-
tics of the particular drugs evaluated, as part of a
bottom-up approach.23
More precisely, following a systematic literature
review and expert consultation as part of the Advance-
HTA project,4,i a generic value tree was developed out-
lining higher level criteria that were decomposed into
lower level criteria for assessing the value of new medi-
cines in the HTA context.22 The structure of this generic
value tree, the Advance Value Tree, consists of five value
domains or criteria clusters, aiming to reflect all the
essential value attributes of new medicines in tandem
with their indication under a prescriptive decision-aid
approach. These include 1) burden of disease (BoD), 2)
therapeutic impact (THE), 3) safety profile (SAF), 4)
innovation level (INN), and 5) socioeconomic impact
(SOC), with the first value domain relating to the disease
of interest and the four latter domains relating to the
actual medical intervention(s), essentially producing the
following value function:
Value= f BoD, THE, SAF, INN , SOCð Þ ð1Þ
In consultation with a clinical oncologist, the generic
value tree was then adapted for the case of mCRPC
i Advance-HTA was a research project funded by the
European Commission’s Seventh Research Framework
Programme (FP7). It was comprised of several complemen-
tary streams of research that aimed to advance and
strengthen the methodological tools and practices relating to
the application and implementation of HTA. It was a part-
nership of 13 consortium members led by the London
School of Economics—LSE Health.
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while striving to adhere to the ideal decision theory prop-
erties to ensure methodological robustness. As a result, a
disease-specific value tree was produced with five criteria
clusters decomposed into eight subcriteria clusters and a
total of 18 emerging criteria attributes (Supplementary
Figure A1 in the Online Appendix). The definitions of
all criteria attributes are listed in Table 1.
Subsequently, the value tree was validated together
with the decision conference participants as part of a
more constructive decision-aid approach allowing for
interactivity and enabling group learning. This ‘‘socio-
technical’’ approach is reflecting another type of mixed
approach adopted in the evaluation (i.e., values construc-
tion): initially, model adaptation and structuring took
place in consultation with a clinical expert, which was
then collectively validated and evaluated with the group
before the completion of the model building phase.45
Evidence Considered and Alternative Treatments
Compared (Model Building)
The alternative treatment options compared in the
analysis were abiraterone (Zytiga) in combination with
prednisone, cabazitaxel (Jevtana) in combination with
prednisone, and enzalutamide (Xtandi) monotherapy.
The evidence sources used included the peer review
publications concerning the pivotal clinical trials of the
alternative treatment options that were considered in the
appraisals of NICE and TLV,33–35,46 the NICE Evidence
Review Group (ERG) reports,47,48 or their relevant peer
review publications,49,50 a Swedish population study on
health related quality of life,51 the Product Information
sections of the European Public Assessment Reports
(EPAR) from the European Medicines Agency (Annex I
and III),52–54 the Anatomical Therapeutic Chemical
(ATC) classification system indexes available through
the portal of the WHO Collaborating Centre for Drug
Statistics Methodology,55 the US National Library of
Medicine database of clinical trials available through
ClinicalTials.gov,56 and the British National Formulary
(BNF).57 The clinical evidence (falling under the THE
and SAF criteria clusters) for each alternative treat-
ment option were sourced from the same clinical stud-
ies that NICE and TLV evaluated (single pivotal trials
for each drug). The source of evidence used for identi-
fying the performance of options across the evaluation
criteria is shown in Table 1. Additional information on
the evidence considered can be found in the Online
Appendix.
Setting Attribute Ranges and References Levels
(Model Building)
With regard to model building, the allowable range of
performance across the different attributes (i.e., attribute
ranges) was selected based on the performance of the
alternative treatment options compared. Within the attri-
bute ranges, ‘‘lower’’ (x_l) and ‘‘higher’’ (x_h) reference
levels were defined to serve as benchmarks for preference
value scores of 0 and 100, respectively, acting as value
anchors for constructing criteria value functions and eli-
citing their relative weights.58,59,ii The ‘‘lower’’ reference
levels denoted less preferred levels aiming to reflect
‘‘satisfactory’’ performance, whereas the ‘‘higher’’ refer-
ence levels denoted more preferred levels aiming to
reflect ‘‘ideal’’ performance. The latter was defined by
considering plausible changes in best available perfor-
mance, for example, by accounting for new product
characteristics that might enter the market in the near
future that could outperform the current ones. The refer-
ence levels of the clinical attributes (under the THE and
SAF value domains) were decided in consultation with a
clinical expert (urologic oncologist). Depending on the
criterion under consideration, the typical rationale
adopted the BSC performance as a ‘‘satisfactory’’ refer-
ence level with a hypothetical performance improvement
of 20% better than the best available option acting as the
‘‘ideal’’ reference level (or vice versa for negative attri-
butes). The 20% hypothetical improvement was selected
because it was deemed to be a realistically plausible clinical
effect of forthcoming products. By considering the perfor-
mance of best available option(s) among the treatments
evaluated in the exercise and accounting for plausible per-
formance improvement in the near future, the value scale
essentially reflected characteristics of both a ‘‘local’’ scale
(benchmarks derived based on the performance of options
evaluated, i.e., what is best available) and a ‘‘global’’ scale
(benchmarks derived based on the plausible performance
of options not necessarily captured in the exercise, i.e.,
what is best plausible).60 The emerging value scores of
options could in theory take negative or higher than 100
values where v(xlower) = 0 and v(xhigher) = 100, essentially
by conducting a linear transformation that is acceptable as
an interval scale such as a value scale. ‘‘Lower’’ and
‘‘higher’’ reference levels for all attributes at the
pre-workshop stage and the basis of their selection are
outlined in Table A1 in the Online Appendix (assuming
ii These are interval scales and therefore it is important to set
up clear bounds/limits for each attribute.
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no impact of LHRH analogue). Additional information
on the methodological basis adopted for setting the min-
max attribute limits and reference levels is provided in the
Online Appendix.
Decision Conference (Model Assessment and
Appraisal)
The model assessment and model appraisal phases of the
exercise took place through a facilitated workshop with
assessors from TLV, taking place as a decision confer-
ence and hosted at the head offices of TLV in
Stockholm, Sweden. In total four experts participated,
including one medical investigator, one pharmacist, and
two health economists. Background material introducing
the scope of the exercise in more detail was sent to the
participants one week before the workshop.
The author acted as an impartial facilitator and
assisted the group’s interaction and thinking about the
decision problem using the preliminary version of the
mCRPC specific value tree (Supplementary Figure A1 in
the Online Appendix) and the relevant data as the mod-
el’s starting point, based on which value judgements and
preferences were elicited on-the-spot.27,61,62 On the day
of the workshop the preliminary model was validated
with the participants by revising it cluster by cluster in
real time through an open discussion, seeking group con-
sensus by adopting an iterative and interactive-model-
building process where debate was encouraged and dif-
ferences of opinion actively sought. More information
on the decision conference is provided in the Online
Appendix.
MCDA Technique (Model Assessment and
Appraisal)
The AVF adopts a value measurement MCDA metho-
dology making use of a simple additive (i.e., linear,
weighted average) aggregation model that assumes pre-
ference independence between the different attributes,
with overall value V(.) of an option a defined by the
equation below22:
V að Þ=
Xm
i= 1
wivi að Þ ð2Þ
where m is the number of evaluation criteria, wivi(a) is the
weighted partial value function of evaluation criterion i
for option a, and V(.)_ is a multi-attribute value function
based on value theory principles.29
Each attribute’s value function correlates the perfor-
mance along an attribute range to a value scale. These
were elicited from the workshop participants using the
Measuring Attractiveness by a Categorical Based
Evaluation Technique (MACBETH), based on MAVT.28
This is a pairwise qualitative comparison approach where
qualitative judgements about the difference of value
between different pairs of attribute levels (e.g., difference
in value between 3 and 6 months overall survival) are
expressed using seven categories (no difference, very
weak difference, weak difference, moderate difference,
strong difference, very strong difference, or extreme dif-
ference in value).63,64 By only requiring such semantic
judgements, which are then converted into a cardinal
(interval) value scale using a mathematical algorithm
with a set of decision rules, MACBETH provides a sim-
ple, interactive, and constructive approach, with various
real-world applications illustrating its usefulness as a
decision support tool65–68; the mathematical foundations
of MACBETH have been extensively described.69 A car-
dinal scale can reveal information about the difference
between its levels, in contrast to an ordinal scale that can
only be used for a more restrictive ranking along its levels
without allowing any arithmetic operations. An indirect
(qualitative) swing weighting technique was applied
involving the MACBETH value judgements to elicit rela-
tive criteria weights,64 given that direct questions of
importance for a criterion that do not take into account
their attribute ranges are known to be one of the most
common mistakes in making value trade-offs.70
In turn, the M-MACBETH software was used as a
support system in order to construct the value tree, eli-
cit criteria value functions (through which options were
scored), assign relative criteria weights through the
MACBETH qualitative swing weighting protocol, com-
bine preference value scores and weights together using
additive aggregation to derive overall weighted prefer-
ence value (WPV) scores, and perform sensitivity anal-
ysis on criteria weights.58,71 The software automatically
performs consistency checks between the qualitative
judgements expressed, and in addition a second consis-
tency check was manually performed by the author to
validate the cardinality, i.e. the interval nature, of the
emerging value scale. This was done by comparing the
sizes of the intervals between the proposed scores and
inviting participants to adjust them if necessary,72 a
requirement that is essential for the application of sim-
ple additive value models. More information regarding
the technical details of MACBETH is available in the
Online Appendix.
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Costs Calculation (Model Assessment and
Appraisal)
Drug costs were calculated according to UK prices (exclud-
ing VAT), pack sizes, and dosage strengths as found in the
BNF57; the recommended dosages and treatment durations
were taken from the pivotal trial for the case of cabazi-
taxel,33 the respective NICE technology appraisal for the
case of enzalutamide,39 and the labelling and package leaflet
(EPAR—Annex III) for the case of abiraterone.54 Vial
wastage was assumed in all calculations. Drug administra-
tion costs for cabazitaxel were kept consistent with the
respective NICE TA.40 The UK perspective was adopted as
a neutral benchmark, partially because of the readily avail-
able data and primarily in order to allow the measurement
of cost(s) in a common unit across a series of similar case
studies in different European countries, so that overall
WPV scores can then be viewed against the same cost
denominator to produce comparable cost-value ratios.
Results
Criteria Validation and Amended Value Tree for
Metastatic Prostate Cancer
Overall, consensus was reached in terms of criteria
inclusion and exclusion with no criteria considered to
be missing. The final version of the value tree, as
emerged following the open discussion with the partici-
pants of the workshop, is shown in Figure 1. In total,
Figure 1 Final value tree for metastatic prostate cancer (post-workshop). Image produced using the M-MACBETH (beta)
software, version 3.0.0.
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10 out of the 18 attributes were removed from the value
tree because they were judged from the participants to
be nonfundamental for the scope of the exercise. Most
of these attributes were part of the innovation level
cluster, with all attributes relating to the ATC classifi-
cation system (five attributes) and spillover effects
(four attributes) being excluded. The only other attri-
bute removed was the PSA (prostate-specific antigen)
response attribute of the therapeutic impact cluster
because it was thought to be redundant, without add-
ing any value on top of the remaining therapeutic
attributes.
An example of a MACBETH value judgements
matrix, its conversion into a value scale, and the respec-
tive scoring of the alternative treatments for the case of
Overall Survival (OS) criterion is described in the Online
Appendix. Effectively all attributes produced almost lin-
ear value scales, either based on quantitative or qualita-
tive performance levels.
Options Performance, Criteria Weights, and
Overall Preference Value Rankings
The performance of the options across the different attri-
butes together with the ‘‘lower’’ and ‘‘higher’’ reference
levels are shown in Table 2.
The overall WPV scores of the options and their
breakdown into their partial value scores across the dif-
ferent criteria attributes with their respective weights are
shown in Table 3. Enzalutamide scored the highest over-
all WPV score of 58.7. Abiraterone and cabazitaxel pro-
duced overall WPV scores of 6.9 and 1.4, respectively,
partially due to their ‘‘negative’’ performance in the
treatment discontinuation attribute, producing absolute
preference value scores of 295.3 and 287.5, respectively,
and WPV scores of 220.2 and 218.6, respectively. This
was due to their performance on the treatment disconti-
nuation attribute (19% and 18%, respectively), which
lay below the lower reference level of the scale (i.e.,
10%). A stacked bar plot of the WPV scores of the
alternative treatments across the attributes is shown in
Figure 2.
The relative weights of importance assigned to the dif-
ferent attributes are shown in Figure 3. By taking into
account the ‘‘lower’’ to ‘‘higher’’ ranges of the attributes,
the greatest relative weights were yielded for the case of
Overall Survival, Treatment Discontinuation, and
Health-Related Quality of Life (with relative magnitudes
of 23, 21, and 15 out of 100, respectively), adding up a
combined relative weight of 60% of the total. With
regard to the total weights assigned across the criteriaT
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clusters, Therapeutic Impact cluster totaled a relative
weight of 44 (three attributes), the Safety Profile cluster
totaled a relative weight of 33 (two attributes), the
Socioeconomic Impact cluster totaled a relative weight
of 15 (single attribute), and the Innovation Level cluster
totaled a relative weight of 7 (two attributes) out of 100.
Value for Money Analysis
By using rounded up cost figures of £24,600 for enzaluta-
mide, £21,900 for abiraterone, and £23,900 for cabazi-
taxel (£22,190 drug cost and £1,710 administration cost)
and dividing them with overall WPV scores, the costs per
MCDA value unit were calculated to be £419, £3,173,
and £17,509, respectively (Table 3). Therefore, in terms
of value-for-money, cabazitaxel is shown to be domi-
nated by abiraterone, being also very close to be domi-
nated by enzalutamide (£500 difference based on the
prices used). Enzalutamide on the other hand is associ-
ated with a higher cost (£2,500 difference) and a higher
overall WPV score (51.8 difference) compared with abir-
aterone. The overall WPV scores of the alternative treat-
ments versus their costs (purchasing costs plus any
administration costs) is provided in the form of a cost-
benefit plot in Figure 4.
Table 3 Overall Weighted Preference Value (WPV) Scores, Partial Preference Value Scores, Relative Weights, Costs, and Cost
per Unit of Value
Lower Level Abiraterone Cabazitaxel Enzalutamide Higher Level Relative Weights
Overall WPV score 0 6.9 1.4 58.7 100 100
Overall survival 0 26.2 17.9 56.3 100 23
Health-related quality of life 0 40.0 40.0 40.0 100 15
Radiographic tumor progression 0 26.5 74.0 66.8 100 6
Treatment discontinuation 0 295.3 287.5 20.0 100 21
Contraindications 0 33.3 0.0 83.3 100 12
Delivery posology 0 100.0 0.0 100.0 100 3
Special instructions 0 0.0 60.0 100.0 100 4
Medical costs impact 0 40.5 19.1 93.7 100 15
Costs (£) 21,900 23,900 24,600
Cost per unit of value 3,173 17,509 419
Figure 2 Stacked bar plot of treatments’ weighted preference value (WPV) scores across all attributes.
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Sensitivity and Robustness Analysis
Parameter uncertainty relating to the estimation of
weights was addressed by conducting deterministic sensi-
tivity analysis. At the end of the workshop, the impact of
baseline weights’ changes on options’ rankings was
explored using one-way sensitivity analysis. In order for
cabazitaxel to become better ranked than abiraterone,
PFS relative weight would have to change from 5.8 to
15.6, Treatment Discontinuation relative weight from
21.2 to 53.9, or Special Instructions relative weight from
4.1 to 12.2. Alternatively, for cabazitaxel to become bet-
ter ranked than enzalutamide, PFS relative weight would
have to change from 5.8 to more than 89.5. Under no sce-
nario abiraterone could have been ranked above enzalu-
tamide. Therefore, conclusions were robust as the
ranking of the treatments was not sensitive to single var-
iations of up to at least 100% along the attributes weight
range. The robustness of the results was also validated by
conducting seven-way sensitivity analysis in the reference
levels of the quantitative attributes using the respective
function of the M-MACBETH software (‘‘Robustness
analysis’’). A simultaneous change of up to 610% across
all of the attribute reference levels would not affect the
ranking of the alternative treatments. This means a
change of 20 points in the value scale between the highest
and the lowest scores for every attribute (i.e. the allow-
able range of eligible scores), did not affect treatments’
ranking. In terms of weighting, a simultaneous change of
63% would be needed for a change in the rankings of
the options to be observed (cabazitaxel to become sec-
ond, abiraterone to become third), with no changes in
the best-ranked option plausible.
Other types of uncertainty also exist, including sto-
chastic uncertainty, structural uncertainty, and heteroge-
neity that could possibly be addressed with other
approaches (or combinations of), such as probabilistic
sensitivity analyses, Bayesian frameworks, fuzzy set the-
ory, or grey theory.73 For instance, if significant
Figure 3 Relative criteria weights stacked bar.
Figure 4 Cost-benefit plot of overall weighted preference value
(WPV) scores versus costs. Image produced using the M-
MACBETH (beta) software, version 3.0.0.
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uncertainty exists with regard to options’ performance
due to sampling variation from clinical trials, or in terms
of criteria weights due to failure to agree on them, the
application of point estimates might be inappropriate in
which case stochastic multi-criteria acceptability analysis
(SMAA) could be used.74
Discussion
This case study demonstrates the application of a new
value framework, the AVF,22 adopting an MCDA meth-
odological process in practice23 for a set of alternative
mCRPC treatments from the perspective of an HTA
agency. Generally, MCDA methods in the context of
HTA could be applied using two different ways, either as
part of a supplementary/incremental approach or a pure/
clean-slate approach.12,23 The former could in theory be
used in combination with economic evaluation tech-
niques to adjust the incremental cost effectiveness ratio
(ICER) through the incorporation of additional para-
meters of value (or benefit criteria), therefore essentially
‘‘tweaking’’ the QALY or any other relevant outcome
measure. The latter refers to deriving value anew, not
necessarily involving the QALY or other value metric
from some type of economic evaluation. The current
application of AVF as part of this case study focuses on
the latter.
In terms of design, implementation, and review of the
analysis, the process adopted is effectively in alignment
with the recent ISPOR good practice guidelines on the
use of MCDA for health care decisions.75 Through a
decision conference, alternative options were assessed
and ranked based on their overall WPV scores reflecting
their performance against a set of evaluation criteria
weighted for their relative importance based on the pre-
ferences of the group, yielding a holistic benefit compo-
nent. In doing so, MACBETH was used as an MCDA
modelling technique to operationalize the AVF in terms
of scoring the treatment options and weighting the rela-
tive importance of the evaluation criteria. Subsequent
consideration of drug costs (purchasing and administra-
tion costs) enabled the estimation of ‘‘cost per unit of
value’’ ratios, which showed a dominance between the
second and third ranked options. Assuming the existence
of well-defined budgets, this approach could be used to
derive MCDA-based cost-benefit ratios, prioritizing the
most efficient funding options with the lowest cost-
benefit ratios until the available budget is exhausted.76
The TLV assessors who participated in the workshop
gave positive feedback about the potential usefulness of
the value framework, having the prospects of acting as a
decision support tool in the evaluation of new medicines.
Main advantages included the feasibility to transparently
assess the performance of the options across a number of
explicit evaluation criteria, while allowing to elicit their
value trade-offs (i.e., their relative importance), but also its
overall facilitative nature in the construction and analysis
of the groups’ value preferences.
It should be highlighted that the decision context
addressed in this case study is a one-off evaluation prob-
lem within a particular disease indication in contrast to
the typical remit of TLV, which involves repeated deci-
sions around the reimbursement of drugs across different
disease areas by considering their opportunity cost
through the use of, flexible or adjusting, willingness to
pay thresholds. Consequently, even the most valuable or
efficient treatment in the exercise could prove to be non–
cost-effective on traditional economic evaluation
grounds. This notion would be supported by the fact
that the breath of the value model captured aspects that
go beyond the formal remit of TLV. Therefore, the
results aim to illustrate the methodology’s feasibility
rather than to inform policy making.
Even under the more restricted context of feasibility
testing, the findings should be interpreted under the spec-
ified MCDA characteristics of the exercise, namely, the
particular decision context defined and the value model
developed. The latter consists of the alternative options
assessed, the evaluation criteria incorporated, the rele-
vant value scales defined, the respective value functions
elicited, and the relative weights elicited. Although more
challenging, the value framework could also be applied
at broader inter-indication levels, aiming to assess treat-
ments for different indications that might require the use
of more generic clinical evaluation criteria and less
disease-specific endpoints, as, for example, the use of
QALY that allows the comparison of health gain across
different populations.
With regard to the removal of the spillover effect
attributes under the innovation level cluster, this took
place on the grounds that they ‘‘currently go beyond the
agency’s remit’’ and therefore should not be considered
in the first place. However, the opinion was evident that
in real practice this information could act as supplemen-
tary type of evidence, not for influencing the coverage of
the respective treatments but possibly for other second-
ary purposes as, for example, awarding reimbursement
extensions or communicating internally possible new
indications in the near future.
The following section discusses some limitations of the
case study and focuses on challenges faced by MCDA
applications in HTA settings and how they could be
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encountered. A more extensive discussion around the
types of strengths and opportunities possibly offered by
the AVF are provided elsewhere, both in terms of rele-
vant practice and policy implications as part of a recent
case study on another oncology indication24 and from a
more theoretical perspective.22
Limitations of the Case Study
The results from the case study should be interpreted
with caution as they comprise the outcome of a simula-
tion exercise aiming to test the AVF in practice by illus-
trating its application rather than to inform real coverage
decision making in respect to the particular drugs under
consideration. Given the absence of head-to-head clinical
trials comparing directly all treatments of interest and
the lack of relative treatment effects across the clinical
attributes of interest, un-synthesized evidence from the
respective single pivotal trials of the alternative treat-
ments were used. However, using un-synthesized evi-
dence from different clinical trials to directly compare
alternative treatments is not accurate, even if the popula-
tions of patients across the different trials are similar (in
terms of disease severity and treatment history). Ideally,
an indirect treatment comparison should be conducted
first by using a common comparator to estimate the rela-
tive effects of two treatments versus the comparator, or a
network meta-analysis that combines both direct and
indirect evidence available through a mixed treatment
comparison.77 Therefore, an important limitation of this
study is the lack of relative effects as part of clinical evi-
dence and the use of their absolute effects from different
clinical trials with the assumption that they can be
directly compared. In real-world evaluations, evidence
synthesis would be required to take place together with
evidence collection as part of the model building phase.
An example can be illustrated through the application of
an SMAA approach for assessing the comparative
benefit-risk of alternative statins in primary prevention,19
using comparative effects from evidence of three meta-
analyses,78–80 or the combination of SMAA with a
network meta-analysis for assessing the comparative
benefit-risk of second-generation antidepressants.81
The relative small number of participants could be per-
ceived as another limitation on the grounds of insignificant
representation of perspectives for the purpose of informing
policy making, but capturing an all-round set of preferences
was not among the primary aims of the exercise. Ideally, a
group size of between 7 and 15 participants should be aimed
for; these sizes allow efficient group processes to emerge
while preserving individuality, as they are large enough to
represent all major perspectives but small enough for work-
ing toward agreement.26 However, it should be noted that
in reality final TLV decisions are made by a separate expert
board/committee within the agency (the Pharmaceuticals
Benefit Board), which consists of only seven members and
whose overall expertise is well aligned with the expertise of
the exercise participants.82
Another issue was that only the HRQoL of the stable
disease state was assessed because none of the treatments
was assumed to have any effects during the progressive
disease state.39 In other disease indications this might not
hold true in which case the relevant HRQoL attribute
would need to capture both the stable and progressive
disease states, possibly in the form of an OS-HRQoL
aggregated attribute (given their possible preference
dependency, discussed below), therefore producing a sim-
ilar metric to QALYs.
Furthermore, another issue which could be perceived
as a limitation was the definition of the ‘‘lower’’ reference
level in the treatment discontinuation attribute and its
impact on scoring, as it could influence the negative par-
tial value scores observed in two of the treatments and
consequently their overall WPV scores. The lower refer-
ence level of 10% used on the basis of Best Supportive
Care performance was sourced from the placebo com-
parator arm of enzalutamide’s pivotal clinical trial
(AFFIRM). The choice of using the placebo arm of the
AFFIRM trial to proxy BSC performance and not the
comparator arm from any of the other two treatments’
pivotal trials was because it better resembled BSC; in
abiraterone’s pivotal trial (COU-AA-301) all patients in
the placebo comparator arm were also administered ster-
oids (prednisone), whereas in cabazitaxel’s pivotal trial
(TROPIC) all patients in the comparator arm were
administered steroids (prednisone or prednisolone) on
top of chemotherapy (mitoxantrone). As a result, abira-
terone and cabazitaxel produced negative partial value
scores in treatment discontinuation as their performance
lay below the lower reference level. The basis adopted
for setting all clinical attribute reference levels is exten-
sively described in the Methods section, and although it
took place in consultation with a clinical expert, others
might have chosen different attribute levels. However,
any such differences would most probably have been of
minor impact, not necessarily affecting the overall valua-
tion or ranking of the treatments.
Challenges of MCDA Applications in HTA
Among the main challenges of MCDA applications in
HTA evaluations include the technical requirements in
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ensuring that all attributes possess the necessary theoreti-
cal properties.83,84
Because of the use of a simple additive (i.e., weighted
average aggregation) model, the violation of preference-
independence is of particular relevance as it might under-
mine the validity of such models.83 There are two types
of preferential independence, at ordinal and cardinal lev-
els, the former of which is a precondition for the latter,
but not vice versa. Intuitively, ordinal preference inde-
pendence means that alternative options can be ranked
on one dimension (e.g., attribute) independently of their
impact on another dimension. In contrast, the notion of
cardinal preference independence, which is also referred
to as ‘‘difference independence,’’85 denotes that the dif-
ference in attractiveness—or added value of an
improvement—between two performance levels on one
criterion (e.g., attributes levels) does not depend and can
be measured independently of the levels on another cri-
terion.86 Such a ‘‘difference consistency’’ between (the
values of the) attributes is often taken as a working
hypothesis given that it is ‘‘so intuitively appealing that it
could simply be assumed to hold in most practical
applications.’’87(p284)
However, evidence suggests potential preference depen-
dencies between health gain and disease severity,88 or over-
all survival and HRQoL.22 Considering the absence of a
disease severity criterion, in order to avoid potential
preference-dependence between the OS and HRQOL attri-
butes and given an equal performance across all options in
terms of the latter, OS value functions derived were effec-
tively conditional on the range of the HRQoL attribute at
a cardinal level. More precisely, the ‘‘lower’’ (x_l) and
‘‘higher’’ (x_h) reference levels of the plausibly dependent
HRQoL attribute (EQ-5D index scores) were revealed to
participants, that is, v(x_0.72) = 0 and v(x_0.82) = 100,
and they were instructed to assume an identical perfor-
mance between the options on the dependent attribute
(given that all three options had identical performance),
but without disclosing the exact figure. However, it should
be noted that the use of such ‘‘conditionally cardinal value
functions’’ might in theory be incompatible with the use of
an additive model and therefore should only be used with
caution, as, for example, within descriptors of perfor-
mance (i.e., attributes).89 Alternatively, a multiplicative
model could be used; see the example of the Thai essential
list.90 In any case, the use of a simple test involving the
combination of Reasoning Maps with MACBETH that
takes the form of a multilinear evaluation model structure
has been proposed as a way to capture potential value
interactions between criteria and therefore cardinal prefer-
ence dependencies.91
Other technical challenges include a possible lack of
connection between attribute ranges (i.e., criteria scales)
and weights, and the incorporation of economic
evaluation–related considerations in the MCDA.84 First,
assigning weights of ‘‘generic importance’’ without con-
sidering the performance of the alternative decision
options being analyzed is known to be one of the most
common mistakes when making value trade-offs.43,70 In
the value framework adopted, elicitation of weights takes
place following the selection of the alternative treatments
and the specification of their performance as part of the
adaptation of the generic Advance Value Tree into a
disease-specific value tree.22 Second, considering the
costs and/or the cost-effectiveness of the options can lead
to theoretical challenges as costs do not represent attri-
butes of benefit whereas the effectiveness component
would have already been captured as part of the relevant
criteria, therefore possibly leading to double-counting.92
Combining both benefits and costs together can also
cause practical hurdles when trying to link the MCDA
results with policy recommendations, as prioritizing
resource allocation would not be a clear task given the
absence of a cost-benefit (or value) ratio that reflects effi-
ciency. Instead, the value framework applied only con-
siders impact on resources without accounting for the
purchasing cost of the options themselves,22 therefore
providing a more comprehensive unit of benefit. Such
benefit units could then be considered in alignment with
the respective costs of the options to derive appropriate
cost-value ratios, which could be used to inform the allo-
cation of resources by understanding the opportunity
cost of different decisions assuming a defined budget,76
possibly as part of a portfolio decision analysis exercise.
Future research could investigate the opportunity cost
associated with disinvestments which could feed the
development of incremental cost value ratio thresholds,
acting as potential cutoff points for efficiency similarly
to current ICER thresholds used in economic evalua-
tions. However, this would face all the current challenges
associated with the technical difficulties in estimating
sound ICER thresholds to reflect opportunity cost.93,94
Conclusion
In health care systems facing significant budgetary pres-
sures, HTA challenges relating to the evaluation of and
resource allocation for innovative treatments require
novel value-based assessment methodologies that can
facilitate preference elicitation and decision making in a
transparent way. Such methodologies should be based
on robust theoretical principles so the results can lead to
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credible decisions. Future research could help validate
the robustness and usefulness of the current value frame-
work by conducting similar case studies with other HTA
and insurer bodies across different European countries.
In order to catalyze the possible implementation of
any such MCDA-based value framework, even at a test-
ing phase, the development of the model and the applica-
tion of the methodology altogether should be aligned
with the formal remit of the decision-makers’ institu-
tions. Establishing clear goals for the role of the results
would be beneficial for the initial exploration of the
methodology. In settings where strict guidelines and
requirements exist around the application of specific
HTA methods, as in Sweden with the use of economic
evaluation, the exploration of a supplementary or ‘‘incre-
mental’’ MCDA mode to cost-effectiveness analysis
might act as a more realistic option for decision makers
so that the results can be more readily adaptable to their
current needs and therefore more easily implementable
in daily practice. In turn, adaptation of a pure or ‘‘clean-
slate’’ mode could still be viable but involving the utiliza-
tion of more concise value trees that restrict the number
of criteria around the formal value concerns currently in
explicit use. This would allow capturing the primary
value concerns as specified by the evaluation guidelines
requirements while still offering the added benefits of
assessing value through a decomposition approach that
could enable the facilitation of decision making through
a stepwise elicitation and transparent construction of
value preferences. Following such a testing phase, deci-
sion makers could acquire important experience and
confidence that could enable them to explore incorporat-
ing any additional value concerns judged to be relevant
to their decisions.
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